
|Videos|September 14, 2018
Modest Response Rates in Endometrial Cancers
Author(s)Vicky Makker, MD
Vicky Makker, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses 2 agents, lenvatinib and pembrolizumab, in patients with endometrial cancers.
Advertisement
Vicky Makker, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses 2 agents, lenvatinib (Lenvima) and pembrolizumab (Keytruda), in patients with endometrial cancers.
While lenvatinib has previously been approved for the treatment of radioactive iodinerefractory differentiated thyroid cancer, as well as in advanced renal cell carcinoma in combination with everolimus (Afinitor), this agent has shown a modest response rate of 14% in patients with heavily pretreated endometrial cancer.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
2
Early Relapse Guides Use of CAR T vs Other Options in LBCL
3
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5









































